Bavarian Nordic AS's lead investigational product, the prostate cancer vaccine Prostvac (rilimogene galvacirepvec), has failed at the Phase III stage, sending the firm's share price down by more than 48% to DKK228.5 on Sept. 15, and raising concerns over potential implications for another of its candidate vaccines.
PROSPECTs Futile For Bavarian Nordic's Prostvac Cancer Vaccine
The Phase III PROSPECT study's data monitoring committee decides against continuing after interim analysis. The fall-out could hit Bavarian Nordic’s CV301 too.
